Peripheral blood CD26 positive leukemic stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia

BACKGROUND: CD26 is expressed in all chronic myeloid leukemia (CML) patients. This study investigated the role of CD26(+) LSCs in diagnosis and follow up of CML patients. METHOD: Flow cytometry was performed to evaluate CD26(+) LSC in peripheral blood (PB) in CML patients. BCR-ABL1 transcript level...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebian, Huda F, Abdelnabi, AL-Shabrawy M., Abdelazem, Abdallah S., Khamis, Tarek, Fawzy, Hebatallah M., Hussein, Samia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118510/
https://www.ncbi.nlm.nih.gov/pubmed/35602932
http://dx.doi.org/10.1016/j.lrr.2022.100321
Descripción
Sumario:BACKGROUND: CD26 is expressed in all chronic myeloid leukemia (CML) patients. This study investigated the role of CD26(+) LSCs in diagnosis and follow up of CML patients. METHOD: Flow cytometry was performed to evaluate CD26(+) LSC in peripheral blood (PB) in CML patients. BCR-ABL1 transcript level measurement was performed using standard qRT-PCR technique. RESULTS: CD26(+) LSCs were significantly correlated with BCR-ABL1 transcript level at diagnosis and after three months of treatment. CD26+ LSCs also were significantly associated with the risk score after 12 months of treatment. CONCLUSION: CD26+ LSCs can be a useful marker in diagnosis and follow up of patients with CML.

Ejemplares similares